EXAS vs MREO · rev $2.76B vs $48.7M cap
EXACT Sciences Corporation (EXAS) versus Mereo BioPharma Group PLC ADR (MREO) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Mereo BioPharma Group PLC ADR (MREO) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported MREO revenue for 2026-06-30 was $0. Net income was -$7.0M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. MREO currently screens at market cap $48.7M.
EXAS currently screens at market cap $20.03B. MREO currently screens at market cap $48.7M.
Not investment advice. Open the EXAS and MREO stock pages for the full models.
Not investment advice.